49 research outputs found
Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° Π°Π»Π³ΠΎΡΠΈΡΠΌΠ° Π΄Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΡΠ»Π°Π±Π»Π΅Π½ΠΈΡ Π»ΡΡΠΈΡΡΠΎΠΉ ΡΠ½Π΅ΡΠ³ΠΈΠΈ ΡΠ»ΠΎΠ΅ΠΌ Π²ΠΎΠ΄Ρ, ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΠΌ ΠΏΡΠ·ΡΡΠΈ Π³Π°Π·Π°
ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΎΠ±ΡΠ΅ΠΌΠ° Π²ΡΡΠΈΡΠ»ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠΎΠ² ΠΏΡΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΠΈ Π·Π°Π΄Π°Ρ ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠΈΠ½ΡΠ΅Π·Π° Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠΈΡΡΠ΅ΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΠΠ-ΠΏΠΎΠΈΡΠΊΠ°
ΠΠ°ΡΡΡΡ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ Π²ΡΠ±ΠΎΡΡ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΠ³ΠΎ ΡΠΈΡΠ»Π° ΠΌΠ°ΡΠΈΠ½Π½ΡΡ
ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠΎΠ² ΠΏΡΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΠΈ ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΡΡ
Π·Π°Π΄Π°Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ΅ΠΊΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΠΠ-ΠΏΠΎΠΈΡΠΊΠ°, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠ΅Π³ΠΎ ΠΎΡΡΡΠ΅ΡΡΠ²Π»ΡΡΡ Π³Π»ΠΎΠ±Π°Π»ΡΠ½ΡΠΉ ΠΊΠ²Π°Π·ΠΈΡΠ°Π²Π½ΠΎΠΌΠ΅ΡΠ½ΡΠΉ ΠΏΡΠΎΡΠΌΠΎΡΡ Π·Π°Π΄Π°Π½Π½ΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ Π²Π°ΡΡΠΈΡΡΠ΅ΠΌΡΡ
ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΠΈ ΠΏΡΠΈΠΌΠ΅Π½ΠΈΡΡ ΡΠΎΡΠΌΠ°Π»ΡΠ½ΡΠ΅ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΈΠ· ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠΈ.Recommendations about the choice of necessary number of machine experiments at the solution of specific objectives of a research and optimum design are made by method of the PLP-search allowing to carry out global quasi uniform viewing of the set area of the varied parameters and to apply formal estimates from mathematical statistics
Matched-pair analysis of patients with female and male breast cancer: a comparative analysis
<p>Abstract</p> <p>Background</p> <p>Male breast cancer (MBC) is a rare disease accounting for approximately 1% of all breast carcinomas. Presently treatment recommendations are derived from the standards for female breast cancer. However, those approaches might be inadequate because of distinct gender specific differences in tumor biology of breast cancer. This study was planned in order to contrast potential differences between female and male breast cancer in both tumor biological behavior and clinical management.</p> <p>Methods</p> <p>MBC diagnosed between 1995-2007 (region Chemnitz/Zwickau, Saxony, Germany) was retrospectively analyzed. Tumor characteristics, treatment and follow-up of the patients were documented. In order to highlight potential differences each MBC was matched with a female counterpart (FBC) that showed accordance in at least eight tumor characteristics (year of diagnosis, age, tumor stage, nodal status, grade, estrogen- and progesterone receptors, HER2 status).</p> <p>Results</p> <p>108 male/female matched-pairs were available for survival analyses. In our study men and women with breast cancer had similar disease-free (DFS) and overall (OS) survival. The 5-years DFS was 53.4% (95% CI, range 54.1-66.3) in men respectively 62.6% (95% CI, 63.5-75.3) in women (p > 0.05). The 5-years OS was 71.4% (95% CI, 62.1-72.7%) and 70.3% (95% CI, 32.6-49.6) in women (p > 0.05). In males DFS analyses revealed progesterone receptor expression as the only prognostic relevant factor (p = 0.006). In multivariate analyses for OS both advanced tumor size (p = 0.01) and a lack of progesterone receptor expression were correlated (p = 0.01) with poor patients outcome in MBC.</p> <p>Conclusion</p> <p>Our comparative study revealed no survival differences between male and female breast cancer patients and gives evidence that gender is no predictor for survival in breast cancer. This was shown despite of significant gender specific differences in terms of frequency and intensity of systemic therapy in favor to female breast cancer.</p
In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer
Autoradiographisch-zellkinetische Untersuchungen zur Proliferation im Jejunum der Ratte unter dem EinfluΓ einer chronischen Niereninsuffizienz
Male Breast Cancer
Breast cancer is a rare disease in men representing nearly 1% of the total breast cancer cases worldwide. Due to the low incidence, there are no randomized clinical studies giving information on the optimal diagnostics and therapy for male breast cancer patients. Therefore, treatment recommendations are derived from established guidelines for breast cancer in women. However, the lack of awareness of this disease leads to its detection at a later stage in men associated with a worse prognostic outcome. The gender-specific differences in breast cancer are among others related to the differing genetic and hormonal environment and the anatomic constitution in men. For example, males have a much higher percentage of hormone receptor-positive tumors but a significantly lower fraction of carcinomas overexpressing HER2. This review focuses on epidemiology, pathogenesis, and clinical findings of male breast cancer, and discusses current findings available to treat this disease. To optimize disease outcome and tolerability of treatment, these data should be considered to improve the therapeutic index of male breast cancer patients